pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
Intrarosa 6.5 mg pessary
Phase 3 · small molecule · Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
Intrarosa 6.5 mg pessary for Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome). is a Phase 3 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Istituto Gentili S.r.l.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
- Status
- active
- Trials
- 1